{"id":"W4415940509","doi":"10.1016/j.annonc.2025.08.1858","title":"1223TiP A randomized phase III study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY-Endometrial01/GOG-3098/ENGOT-EN24","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University","funders":"Genentech; National Institutes of Health; PharmaMar; Sociedad Española de Oncología Médica; Eisai; Seagen; NRG Oncology; Incyte; Novocure; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Daiichi Sankyo Europe; U.S. Department of Defense; Sanofi; Amgen; Intuitive Surgical; Pfizer; Minnesota Ovarian Cancer Alliance; Gilead Sciences","keywords":"Pembrolizumab; Trastuzumab; Chemotherapy; Endometrial cancer; Phases of clinical research; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000836437,0.001164748,0.001613301,0.000296349,0.0003696367,0.001036186,0.0007152968,0.001299205,0.01141578],"category_scores_gemma":[0.0007166595,0.0005341282,0.001203775,0.000313571,0.0007418642,0.0007276314,0.0002625147,0.002761457,0.001945736],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009036104,"about_ca_system_score_gemma":0.001362097,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001187064,"about_ca_topic_score_gemma":0.003800053,"domain_scores_codex":[0.9996796,0.0001488115,0.00001452678,0.00005905791,0.0000198278,0.00007826694],"domain_scores_gemma":[0.9996023,0.00006389405,0.00006184631,0.00003359224,0.00002103613,0.0002173352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9280576,0.01677725,0.001482935,0.0003476382,0.000897155,0.00007707915,0.00004942964,0.0006635707,0.008980132,0.0002276797,0.003901995,0.03853756],"study_design_scores_gemma":[0.9101707,0.08394777,0.002526126,0.00001567285,0.0002741343,0.00004297328,0.00001477748,0.0004222741,0.000669568,0.00008886516,0.00181482,0.00001222663],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9794092,0.003207791,0.0007815633,0.001196303,0.0007079304,0.004121002,0.003586377,0.0002205642,0.006769377],"genre_scores_gemma":[0.9743027,0.001989791,0.001860525,0.002214596,0.0004340096,0.003977312,0.005453409,0.00005703988,0.009710661],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01141578,"threshold_uncertainty_score":0.03818959,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05491755407301094,"score_gpt":0.390436626068399,"score_spread":0.335519071995388,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}